Determine prognosis in myelodysplastic sydnrome
Myelodysplastic syndromes are a heterogeneous group of diseases with variable outcomes. Patients with low-risk disease often have longer survivals and the primary therapeutic goals include improvement of ineffective hematopoiesis and reduction of iron overload. Higher risk patients are managed with the goal of delaying transformation to acute leukemia and extending survival. The International Prognostic Scoring System is the most commonly used tool in MDS to predict long-term outcome.
Greenberg et al
Myelodysplastic syndromes are a heterogeneous group of diseases with variable outcomes. Patients with low-risk disease often have longer survivals and the primary therapeutic goals include improvement of ineffective hematopoiesis and reduction of iron overload. Higher risk patients are managed with the goal of delaying transformation to acute leukemia and extending survival. The International Prognostic Scoring System is the most commonly used tool in MDS to predict long-term outcome.
Greenberg et al
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
